1. Home
  2. CERT vs SUPN Comparison

CERT vs SUPN Comparison

Compare CERT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERT
  • SUPN
  • Stock Information
  • Founded
  • CERT 2008
  • SUPN 2005
  • Country
  • CERT United States
  • SUPN United States
  • Employees
  • CERT N/A
  • SUPN N/A
  • Industry
  • CERT Retail: Computer Software & Peripheral Equipment
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERT Technology
  • SUPN Health Care
  • Exchange
  • CERT Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • CERT 2.3B
  • SUPN 2.1B
  • IPO Year
  • CERT 2020
  • SUPN 2012
  • Fundamental
  • Price
  • CERT $13.17
  • SUPN $33.05
  • Analyst Decision
  • CERT Buy
  • SUPN Hold
  • Analyst Count
  • CERT 7
  • SUPN 2
  • Target Price
  • CERT $15.92
  • SUPN $36.00
  • AVG Volume (30 Days)
  • CERT 1.4M
  • SUPN 464.2K
  • Earning Date
  • CERT 02-26-2025
  • SUPN 02-25-2025
  • Dividend Yield
  • CERT N/A
  • SUPN N/A
  • EPS Growth
  • CERT N/A
  • SUPN 130.79
  • EPS
  • CERT N/A
  • SUPN 1.07
  • Revenue
  • CERT $372,797,000.00
  • SUPN $651,972,000.00
  • Revenue This Year
  • CERT $10.48
  • SUPN $7.94
  • Revenue Next Year
  • CERT $9.94
  • SUPN N/A
  • P/E Ratio
  • CERT N/A
  • SUPN $31.70
  • Revenue Growth
  • CERT 5.62
  • SUPN 6.79
  • 52 Week Low
  • CERT $9.41
  • SUPN $25.53
  • 52 Week High
  • CERT $19.87
  • SUPN $40.28
  • Technical
  • Relative Strength Index (RSI)
  • CERT 48.29
  • SUPN 32.98
  • Support Level
  • CERT $13.54
  • SUPN $32.53
  • Resistance Level
  • CERT $15.69
  • SUPN $39.99
  • Average True Range (ATR)
  • CERT 0.70
  • SUPN 1.31
  • MACD
  • CERT -0.16
  • SUPN -0.69
  • Stochastic Oscillator
  • CERT 2.70
  • SUPN 6.71

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: